Skip to main content
Top
Published in: Journal of Bone and Mineral Metabolism 2/2015

01-03-2015 | Original Article

Effect of Urocortin on strength and microarchitecture of osteopenic rat femur

Authors: Mohammad Tezval, Silja Hansen, Ulrich Schmelz, Marina Komrakova, Klaus Michael Stuermer, Stephan Sehmisch

Published in: Journal of Bone and Mineral Metabolism | Issue 2/2015

Login to get access

Abstract

As yet there is no evidence of the potential antiosteoporotic effect of Urocortin-1 (UCN), a corticotropin releasing factor related peptide, in vivo. In this study, and for the first time, we investigated the effect of UCN in a rat osteopenia model. Sixty female Sprague–Dawley rats were divided into 5 groups: (1) sham-operated, (2) untreated ovariectomized (OVX) rats, (3) and (4) OVX animals treated for 5 weeks with daily subcutaneous low-dose UCN (3 μg/kg of BW) or high-dose UCN (30 μg/kg of BW) 8 weeks after ovariectomy, and (5) OVX rats treated with daily estrogen (0.2 mg/kg of BW p.o) 8 weeks after ovariectomy for 5 weeks (E). After sacrifice, the femurs were reserved for biomechanical, histomorphometric and ash testing. In the biomechanical test, the high-dose UCN rats showed significantly improved mechanical stiffness (341.6 N/mm) compared with the untreated OVX animals (275.9 N/mm). In the histomorphometric evaluation, the high-dose UCN rats demonstrated an improved trabecular microarchitecture especially and significantly at the distal femur (distal femur Tb.Ar = 41.4 % and N.Nd/mm2 = 26.8, proximal femur Tb.Ar = 71.8 % and N.Nd/mm2 = 28.7) compared with untreated OVX rats (distal femur Tb.Ar = 23.3 % and N.Nd/mm2 = 11.7, proximal femur Tb.Ar = 60.2 % and N.Nd/mm2 = 25.2). Our results show that short-term treatment with UCN seems to have a positive effect on the metaphyseal bone structure and strength of the femur in ovariectomized rats.
Literature
1.
go back to reference Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, Chan R, Turnbull AV, Lovejoy D, Rivier C et al (1995) Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378:287–292CrossRefPubMed Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, Chan R, Turnbull AV, Lovejoy D, Rivier C et al (1995) Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378:287–292CrossRefPubMed
2.
go back to reference Boorse GC, Denver RJ (2006) Widespread tissue distribution and diverse functions of corticotropin-releasing factor and related peptides. Gen Comp Endocrinol 146:9–18CrossRefPubMed Boorse GC, Denver RJ (2006) Widespread tissue distribution and diverse functions of corticotropin-releasing factor and related peptides. Gen Comp Endocrinol 146:9–18CrossRefPubMed
3.
go back to reference Bale TL, Hoshijima M, Gu Y, Dalton N, Anderson KR, Lee KF, Rivier J, Chien KR, Vale WW, Peterson KL (2004) The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proc Natl Acad Sci USA 101:3697–3702CrossRefPubMedCentralPubMed Bale TL, Hoshijima M, Gu Y, Dalton N, Anderson KR, Lee KF, Rivier J, Chien KR, Vale WW, Peterson KL (2004) The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proc Natl Acad Sci USA 101:3697–3702CrossRefPubMedCentralPubMed
4.
go back to reference Fekete EM, Zorrilla EP (2007) Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs. Front Neuroendocrinol 28:1–27CrossRefPubMedCentralPubMed Fekete EM, Zorrilla EP (2007) Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs. Front Neuroendocrinol 28:1–27CrossRefPubMedCentralPubMed
5.
go back to reference Chatzaki E, Euthymiadis C, Kyriaki S, Lambropoulou M, Tsaroucha A, Laftsidis P, Simopoulos K (2005) Urocortin and corticotropin-releasing hormone receptor type 2 expression in the human gallbladder. Neuroendocrinology 82:177–184CrossRefPubMed Chatzaki E, Euthymiadis C, Kyriaki S, Lambropoulou M, Tsaroucha A, Laftsidis P, Simopoulos K (2005) Urocortin and corticotropin-releasing hormone receptor type 2 expression in the human gallbladder. Neuroendocrinology 82:177–184CrossRefPubMed
6.
go back to reference Slominski A, Wortsman J (2000) Neuroendocrinology of the skin. Endocr Rev 21:457–487PubMed Slominski A, Wortsman J (2000) Neuroendocrinology of the skin. Endocr Rev 21:457–487PubMed
7.
go back to reference Henry B, Vale W, Markou A (2006) The effect of lateral septum corticotropin-releasing factor receptor 2 activation on anxiety is modulated by stress. J Neurosci 26:9142–9152CrossRefPubMed Henry B, Vale W, Markou A (2006) The effect of lateral septum corticotropin-releasing factor receptor 2 activation on anxiety is modulated by stress. J Neurosci 26:9142–9152CrossRefPubMed
8.
go back to reference Fatima A, Andrabi S, Wolf G, Engelmann M, Spina MG (2013) Urocortin 1 administered into the hypothalamic supraoptic nucleus inhibits food intake in freely fed and food-deprived rats. Amino acids 44:879–885 Fatima A, Andrabi S, Wolf G, Engelmann M, Spina MG (2013) Urocortin 1 administered into the hypothalamic supraoptic nucleus inhibits food intake in freely fed and food-deprived rats. Amino acids 44:879–885
9.
go back to reference Tezval M, Tezval H, Dresing K, Stuermer EK, Blaschke M, Stuermer KM, Siggelkow H (2009) Differentiation dependent expression of urocortin’s mRNA and peptide in human osteoprogenitor cells: influence of BMP-2, TGF-beta-1 and dexamethasone. J Mol Histol 40:331–341CrossRefPubMedCentralPubMed Tezval M, Tezval H, Dresing K, Stuermer EK, Blaschke M, Stuermer KM, Siggelkow H (2009) Differentiation dependent expression of urocortin’s mRNA and peptide in human osteoprogenitor cells: influence of BMP-2, TGF-beta-1 and dexamethasone. J Mol Histol 40:331–341CrossRefPubMedCentralPubMed
10.
go back to reference Combs CE, Fuller K, Kumar H, Albert AP, Pirianov G, McCormick J, Locke IC, Chambers TJ, Lawrence KM (2012) Urocortin is a novel regulator of osteoclast differentiation and function through inhibition of a canonical transient receptor potential 1-like cation channel. J Endocrinol 212:187–197CrossRefPubMed Combs CE, Fuller K, Kumar H, Albert AP, Pirianov G, McCormick J, Locke IC, Chambers TJ, Lawrence KM (2012) Urocortin is a novel regulator of osteoclast differentiation and function through inhibition of a canonical transient receptor potential 1-like cation channel. J Endocrinol 212:187–197CrossRefPubMed
11.
go back to reference Bagi CM, Berryman E, Moalli MR (2011) Comparative bone anatomy of commonly used laboratory animals: implications for drug discovery. Comp Med 61:76–85PubMedCentralPubMed Bagi CM, Berryman E, Moalli MR (2011) Comparative bone anatomy of commonly used laboratory animals: implications for drug discovery. Comp Med 61:76–85PubMedCentralPubMed
12.
go back to reference Tezval M, Stuermer EK, Sehmisch S, Rack T, Stary A, Stebener M, Konietschke F, Stuermer KM (2010) Improvement of trochanteric bone quality in an osteoporosis model after short-term treatment with parathyroid hormone: a new mechanical test for trochanteric region of rat femur. Osteoporosis Int J Establ Result Coop Eur Foundation Osteoporos Natl Osteoporos Foundation USA 21:251–261CrossRef Tezval M, Stuermer EK, Sehmisch S, Rack T, Stary A, Stebener M, Konietschke F, Stuermer KM (2010) Improvement of trochanteric bone quality in an osteoporosis model after short-term treatment with parathyroid hormone: a new mechanical test for trochanteric region of rat femur. Osteoporosis Int J Establ Result Coop Eur Foundation Osteoporos Natl Osteoporos Foundation USA 21:251–261CrossRef
13.
go back to reference Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595–610CrossRefPubMed Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595–610CrossRefPubMed
14.
go back to reference Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM (2013) Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. 1:2–17 J Bone Miner Res Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM (2013) Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. 1:2–17 J Bone Miner Res
15.
go back to reference Nazarloo HP, Buttrick PM, Saadat H, Dunn AJ (2006) The roles of corticotropin-releasing factor-related peptides and their receptors in the cardiovascular system. Curr Protein Pept Sci 7:229–239CrossRefPubMed Nazarloo HP, Buttrick PM, Saadat H, Dunn AJ (2006) The roles of corticotropin-releasing factor-related peptides and their receptors in the cardiovascular system. Curr Protein Pept Sci 7:229–239CrossRefPubMed
16.
go back to reference Moffatt JD, Lever R, Page CP (2006) Activation of corticotropin-releasing factor receptor-2 causes bronchorelaxation and inhibits pulmonary inflammation in mice. Faseb J 20:1877–1879CrossRefPubMed Moffatt JD, Lever R, Page CP (2006) Activation of corticotropin-releasing factor receptor-2 causes bronchorelaxation and inhibits pulmonary inflammation in mice. Faseb J 20:1877–1879CrossRefPubMed
17.
go back to reference Lawrence KM, Latchman DS (2006) The Urocortins: mechanisms of cardioprotection and therapeutic potential. Mini Rev Med Chem 6:1119–1126CrossRefPubMed Lawrence KM, Latchman DS (2006) The Urocortins: mechanisms of cardioprotection and therapeutic potential. Mini Rev Med Chem 6:1119–1126CrossRefPubMed
19.
go back to reference Kageyama K, Hanada K, Nigawara T, Moriyama T, Terui K, Sakihara S, Suda T (2006) Urocortin induces interleukin-6 gene expression via cyclooxygenase-2 activity in aortic smooth muscle cells. Endocrinology 147:4454–4462CrossRefPubMed Kageyama K, Hanada K, Nigawara T, Moriyama T, Terui K, Sakihara S, Suda T (2006) Urocortin induces interleukin-6 gene expression via cyclooxygenase-2 activity in aortic smooth muscle cells. Endocrinology 147:4454–4462CrossRefPubMed
20.
go back to reference Wang L, Stengel A, Goebel-Stengel M, Shaikh A, Yuan PQ, Tache Y (2013) Intravenous injection of urocortin 1 induces a CRF(2) mediated increase in circulating ghrelin and glucose levels through distinct mechanisms in rats. Peptides 39:164–170 Wang L, Stengel A, Goebel-Stengel M, Shaikh A, Yuan PQ, Tache Y (2013) Intravenous injection of urocortin 1 induces a CRF(2) mediated increase in circulating ghrelin and glucose levels through distinct mechanisms in rats. Peptides 39:164–170
21.
go back to reference Wang L, Stengel A, Goebel M, Martinez V, Gourcerol G, Rivier J, Tache Y (2011) Peripheral activation of corticotropin-releasing factor receptor 2 inhibits food intake and alters meal structures in mice. Peptides 32:51–59CrossRefPubMedCentralPubMed Wang L, Stengel A, Goebel M, Martinez V, Gourcerol G, Rivier J, Tache Y (2011) Peripheral activation of corticotropin-releasing factor receptor 2 inhibits food intake and alters meal structures in mice. Peptides 32:51–59CrossRefPubMedCentralPubMed
Metadata
Title
Effect of Urocortin on strength and microarchitecture of osteopenic rat femur
Authors
Mohammad Tezval
Silja Hansen
Ulrich Schmelz
Marina Komrakova
Klaus Michael Stuermer
Stephan Sehmisch
Publication date
01-03-2015
Publisher
Springer Japan
Published in
Journal of Bone and Mineral Metabolism / Issue 2/2015
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-014-0578-6

Other articles of this Issue 2/2015

Journal of Bone and Mineral Metabolism 2/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.